Desired Technology Innovations to Prevent Cardiovascular Disease

Panelists discuss desired innovations in health care technology, as well as incentives to further integrate these new technologies into patient care.

EP: 1.Disparities in Cardiovascular Care for Diverse Populations

EP: 2.Innovation vs Access: Supporting Underserved Communities

EP: 3.Exploring Polypharmacy: Adherence, Communication, and Outcomes

EP: 4.Gender-Based Disparities in Cardiovascular Disease

EP: 5.Peripheral Arterial Disease Awareness for Minority Populations

EP: 6.Community Partnership: Increasing Public Awareness of CVD

EP: 7.Recent Data Reveals Disparities in Cardiovascular Care

EP: 8.Identifying Social Determinants of Health in Cardiovascular Care

EP: 9.Impact of Novel Medications and Out-Of-Pocket Costs in Managing Cardiovascular Disease

EP: 10.Developing Practical Solutions to Improve Cardiovascular Care

EP: 11.Advancing Cardiovascular Care Through Technological Innovation

Now Viewing

EP: 12.Desired Technology Innovations to Prevent Cardiovascular Disease

EP: 13.Measuring Implicit Bias

EP: 14.Achieving Equitable Representation in Clinical Studies

EP: 15.Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion

Related Videos

Related Content

Advertisement

July 11th 2025

GLP-1 Receptor Agonists Show Promise as Adjunctive Treatment for Ovarian Cancer

Brooke McCormick

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, offering a promising adjunct to traditional treatments.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 10th 2025

SGLT2 Inhibitor Offers Kidney Protection and Reduces Heart Failure Risk After Acute Myocardial Infarction

Giuliana Grossi

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 8th 2025

Severe COVID-19 Linked to Higher Exacerbation, Mortality Risks in Patients With Bronchiectasis

Brooke McCormick

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.

July 8th 2025

Encounter-Level Factors Drive Racial Disparities in COVID-19 Treatment Access

Brooke McCormick

Encounter-level factors played a key role in limiting outpatient COVID-19 treatment for Black and Latino patients.

Related Content

Advertisement

July 11th 2025

GLP-1 Receptor Agonists Show Promise as Adjunctive Treatment for Ovarian Cancer

Brooke McCormick

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, offering a promising adjunct to traditional treatments.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 10th 2025

SGLT2 Inhibitor Offers Kidney Protection and Reduces Heart Failure Risk After Acute Myocardial Infarction

Giuliana Grossi

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 8th 2025

Severe COVID-19 Linked to Higher Exacerbation, Mortality Risks in Patients With Bronchiectasis

Brooke McCormick

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.

July 8th 2025

Encounter-Level Factors Drive Racial Disparities in COVID-19 Treatment Access

Brooke McCormick

Encounter-level factors played a key role in limiting outpatient COVID-19 treatment for Black and Latino patients.